百克生物：Ⅱ型单纯疱疹病毒mRNA疫苗临床试验获批

Company Update - Baike Biotech (688276) received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for LVRNA101, an mRNA vaccine targeting HSV-2 (herpes simplex virus type 2) to prevent genital herpes [1] Industry Context - There are currently no successfully developed and marketed vaccines globally for HSV-2 or related conditions [2]